...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Cardiology >Comparison of the Usefulness of Enoxaparin Versus Warfarin for Prevention of Left Ventricular Mural Thrombus After Anterior Wall Acute Myocardial Infarction
【24h】

Comparison of the Usefulness of Enoxaparin Versus Warfarin for Prevention of Left Ventricular Mural Thrombus After Anterior Wall Acute Myocardial Infarction

机译：依诺肝素与华法林对预防前壁急性心肌梗死后左室壁血栓形成的作用比较

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Left ventricular (LV) thrombus is one of the most comment complications in patients with anterior acute myocardial infarction (AMI) and LV dysfunction. Although anticoagulation is frequently prescribed, data regarding the appropriate drug, duration, risks, and effect on echocardiographic indices of thrombus are lacking. Moreover, given the difficulty in obtaining adequate anticoagulation with warfarin, it is possible that short-term treatment with a more predictable agent would be effective. We randomized 60 patients at high risk of developing LV mural thrombus (anterior acute myocardial infarction with Q waves and ejection fraction <= 40%) to receive either enoxaparin 1 mg/kg (maximum 100 mg) subcutaneously every 12 hours for 30 days or traditional anticoagulation (intravenous heparin followed by oral warfarin for 3 months). Clinical evaluations and transthoracic echocardiograms were obtained at baseline, in-hospital, and at 3.5 months. There were no differences between the groups regarding baseline demographics, acute echocardiographic findings, and in-hospital outcomes. The length of hospital stay tended to be shorter for the enoxaparin group (4.6 vs 5.6; p = 0.066) and the corresponding hospital costs ($25,837 vs $34,666; p = 0.18). At 3 months, bleeding and thromboembolic events were rare and similar between enoxaparin and warfarin groups. Although more patients had probable mural thrombus in the enoxaparin group compared with warfarin at 3.5 months (15% vs 4%; p = 0.35), this was not significantly different. In conclusion, the use of enoxaparin tends to shorten hospitalization and lower cost of care. However, at 3.5 months, there appears to be numerically higher (but statistically insignificant) rates of LV thrombus in the enoxaparin group. (C) 2015 Elsevier Inc. All rights reserved.
机译：左心室（LV）血栓是患有急性急性心肌梗死（AMI）和LV功能障碍的患者中最引人注目的并发症之一。尽管经常处方抗凝治疗，但缺乏有关适当药物，持续时间，风险以及对血栓超声心动图指标影响的数据。而且，由于难以用华法令获得充分的抗凝作用，所以短期内用更可预测的药物治疗可能是有效的。我们将60例发生左室壁血栓高风险（Q波且射血分数<= 40％的急性急性心肌梗死）高危患者随机分为30天或每12小时皮下注射依诺肝素1 mg / kg（最大100 mg）抗凝（静脉给予肝素，然后口服华法林3个月）。在基线，住院期间和3.5个月时获得临床评估和经胸超声心动图。两组之间在基线人口统计学，急性超声心动图检查结果和院内结局方面无差异。依诺肝素组的住院时间往往较短（4.6比5.6; p = 0.066）和相应的住院费用（25,837美元对34,666美元; p = 0.18）。在3个月时，依诺肝素和华法林组之间很少发生出血和血栓栓塞事件，并且相似。尽管与华法林相比，依诺肝素组在3.5个月时有更多的患者可能出现壁血栓（15％比4％; p = 0.35），但差异无统计学意义。总之，使用依诺肝素会缩短住院时间并降低护理成本。然而，依诺肝素组在3.5个月时，LV血栓的发生率在数字上更高（但在统计学上不显着）。 （C）2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号